Literature DB >> 15722005

Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.

Yun Long Tan1, Dong Feng Zhou, Xiang Yang Zhang.   

Abstract

Neurodegenerative processes may be involved in the pathogenesis of tardive dyskinesia (TD). Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) plays a critical role in the maintenance of functional neurons. The present study was to examine plasma BDNF levels and the relationship among BDNF level, psychopathological and tardive dyskinesia symptoms in schizophrenic patients with TD. Eighty schizophrenic patients with TD were compared with 45 schizophrenic patients without TD, as well as with 45 age-, sex-matched normal controls. The severity of TD was assessed using the Abnormal Involuntary Movement Scale (AIMS). The psychopathology of patients was assessed by the Positive and Negative Syndrome Scale (PANSS). Plasma BDNF levels were measured by sandwich enzyme-linked immunosorbent assay (ELISA). The results showed that the patients with TD had lower plasma BDNF levels than those without TD, and than that of normal controls. In the patients with TD, plasma BDNF levels was inversely correlated with AIMS total score, and with PANSS negative subscore. Female patients had significantly lower plasma BDNF levels than male TD patients. Our results suggest that decreased BDNF may play an important role in the pathophysiology of TD. There may be a relationship between decreased BDNF levels and dyskinetic movements associated with TD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722005     DOI: 10.1016/j.schres.2004.08.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

2.  The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy.

Authors:  Meneka K Sidhu; Pamela J Thompson; Britta Wandschneider; Alexandra Foulkes; Jane de Tisi; Jason Stretton; Marina Perona; Maria Thom; Silvia B Bonelli; Jane Burdett; Elaine Williams; John S Duncan; Mar Matarin
Journal:  CNS Neurosci Ther       Date:  2018-06-27       Impact factor: 5.243

3.  Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Authors:  D L Kelly; E Weiner; M P Ball; R P McMahon; W T Carpenter; R W Buchanan
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

4.  BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Authors:  Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

5.  Neuromodulatory propensity of Bacopa monniera against scopolamine-induced cytotoxicity in PC12 cells via down-regulation of AChE and up-regulation of BDNF and muscarnic-1 receptor expression.

Authors:  M D Pandareesh; T Anand
Journal:  Cell Mol Neurobiol       Date:  2013-07-04       Impact factor: 5.046

6.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

7.  Control of extracellular cleavage of ProBDNF by high frequency neuronal activity.

Authors:  Guhan Nagappan; Eugene Zaitsev; Vladimir V Senatorov; Jianmin Yang; Barbara L Hempstead; Bai Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

Review 8.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

9.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

10.  Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway.

Authors:  Hebatalla I Ahmed; Somaia A Abdel-Sattar; Heba S Zaky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.